NCT03154294 2024-07-26
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
Avera McKennan Hospital & University Health Center
Phase 1 Completed
Clinical Trials
11 trialsNCT03097328 2024-04-29
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02244463 2024-01-12
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT03193853 2023-08-07
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Baylor Research Institute
Phase 2 Completed
NCT02987959 2022-10-14
Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas
Fox Chase Cancer Center
Phase 2 Terminated
NCT02575339 2022-07-26
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT02719691 2022-07-25
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
University of Colorado, Denver
Phase 1 Completed
NCT02988986 2021-09-22
ANETT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT02514824 2020-12-29
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02727777 2020-03-12
Phase II Study of TAK228 in Relapsed Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02091531 2019-11-21
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Completed